Structure Therapeutics’ lead drug candidate is chasing big pharmaceutical rivals in the race for new oral weight-loss medications, and the company had been telling investors to expect data late this ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

AMES, Iowa – Edward Yu took note of the facts – nearly 2 million deaths each year, 9 million infected each year, developments of multidrug-resistant, extensively drug-resistant and now totally ...

Researchers at Scripps Research have redesigned fentanyl at the molecular level, challenging decades-old assumptions about ...

With the world continuing to pack on pounds, there is an urgent need for effective weight management in an increasingly health-conscious world. According to an industry report, the global weight-loss ...

A drug called lenacapavir, an anti-HIV medicine produced by Gilead Sciences, made news this summer after a Phase 3 clinical trial of 5,300 women in Uganda and South Africa found that it was 100% ...

Chemical structures called cyclopropanes can increase the potency of many drugs, but traditional methods to create this structure require highly reactive -- potentially explosive -- ingredients. Now, ...

Modified molecule shows diminished respiratory depression—the leading cause of opioid overdose deaths—while retaining full ...

Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. JPMorgan initiated the company at "Overweight" with a $65 price target, representing 80% potential upside ...